APICES CRO is pleased to announce its contribution to the CANTABRICO study. This is a Phase IIIb clinical trial in Small Cell Lung Cancer (SCLC), recently featured in the Elsevier Lung Cancer Journal. The study evaluates first-line treatment in…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in PALBOBIN Trial, a Phase IB clinical trial in Breast Cancer (TNBC). This acknowledgement was highlighted in the Journal of Cancer Research Communications. APICES…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the CABOMAYOR Trial, a Phase II clinical trial in metastatic renal cell carcinoma (mRCC). This acknowledgement was highlighted in the Journal of Geriatric…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the GGCP 081/21 study, an Observational retrospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Clinical and Translational…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the LOADH study, an Observational prospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Cancer Research and Clinical…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the BEATcc study, an International (EU, USA, APAC) Phase III clinical trial in cervical cancer. This acknowledgement was highlighted during an oral presentation…
We want to share the acknowledgment that APICES has received in ORIGEN study, which is a NSCLC retrospective study, published in the ESMO 2023 congress, in which APICES has collaborated in start-up, project management, monitoring, biostatistics, and medical…
We want to share that APICES is an author and has received acknowledgment in the NALOPOOL study, which is a Real-World Data (RWD) study on opioid-induced constipation in cancer patients, published in Cancers. Moreover, APICES also contributed to…
We want to share the acknowledgment that APICES has received in PARASEC study, which is a prostate cancer retrospective study, published in the ASCO GU 2025 congress, in which APICES has collaborated in start-up, project management, monitoring, biostatistics,…
We want to share the acknowledgment that APICES has received in PRISMA-1 study, which is a phase II bladder cancer trial, published in the ASCO GU 2025 congress, in which APICES has collaborated in start-up, project management, and…
